Trial · NCT04577820
Registered outcomes41
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 41
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET | Baseline and week 56 | |
| Secondary | Change in total lesion activity by PET | Baseline and week 28 | |
| Secondary | Change in total lesion activity by PET | Baseline and week 56 | |
| Secondary | Percent change in total lesion activity by PET | Baseline and week 28 | |
| Secondary | Percent change in total lesion activity by PET | Baseline and week 56 | |
| Secondary | Change in the total volume of HO lesions as assessed by CT | Baseline and week 28 | |
| Secondary | Change in the total volume of HO lesions as assessed by CT | Baseline and week 56 | |
| Secondary | Percent change in the total volume of HO lesions as assessed by CT | Baseline and week 28 | |
| Secondary | Percent change in the total volume of HO lesions as assessed by CT | Baseline and week 56 | |
| Secondary | Change in number of HO lesions as assessed by PET | Baseline and week 28 | HO lesions defined as target and new lesions relative to baseline. |
| Secondary | Change in number of HO lesions as assessed by PET | Baseline and week 56 | Defined above |
| Secondary | Change in the number of HO lesions detectable by CT | Baseline and week 28 | Defined above |
| Secondary | Change in the number of HO lesions detectable by CT | Baseline and week 56 | Defined above |
| Secondary | Time-weighted average (standardized area under curve [AUC]) change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS) | Baseline through week 28 | The NRS is a categorical rating scale used by patients to rate their pain associated with FOP. Patients will be asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain). |
| Secondary | Time-weighted average (standardized AUC) change in daily pain due to FOP, as measured using the daily NRS | Baseline through week 56 | |
| Secondary | Total dosage of glucocorticoids use | Through week 56 | |
| Secondary | Incidence and severity of TEAEs | Through week 56 | |
| Secondary | Concentration of total activin A in serum over time | Through week 56 | |
| Secondary | Pharmacokinetic (Pk) Profile - concentrations of garetosmab in serum over time | Through week 56 | |
| Secondary | Immunogenicity as measured by Anti-drug antibodies (ADA) to garetosmab over time | Through week 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04577820/registered?page=2